|
|
|
|
||
Re: BofA out with another negative piece on Novavax Institutions reporting their positions as of 3/31 are simply using the closing price of NVAX on 3/31. That price was $73.65. If they manage assets greater than $100 mill they have until 45 days post qtr end to report. Some get it done faster than the required 5/15 date. It is NOT premeditated or done in concert it is simply reporting as per SEC rules. The heading "average share price paid" is inaccurate. |
return to message board, top of board |
Msg # | Subject | Author | Recs | Date Posted |
179291 | Re: New PR states that the FDA “WILL” review Novavax on June 7th. Last line: “The U.S. FDA’s Vaccines and Related Biological Products Advisory Committee will review the Novavax COVID-19 vaccine for active immunization against SARS-CoV-2 during a meeting s | redplate | 4 | 5/26/2022 12:52:12 AM |